In the end, all living things—even the cells in our bodies—must die. But what if we could delay the inevitable, even just for a bit? What new scientific advances could come as a result?

In research published this week in the FASEB Journal, scientists at the Stanford University School of Medicine have devised a new method that gives aging DNA a molecular facelift.

Stanford stem cell scientist Helen Blau and her team at the Baxter Laboratory for Stem Cell Biology developed a procedure that physically lengthens telomeres. Telomeres are protective caps on chromosome ends that guard cells from aging.

At birth, our cells carry chromosomes with full‑length telomeres. With every round of cell division, those telomeres shrink. Eventually, they become so short that chromosomes can no longer replicate effectively. For the cell, this marks the beginning of decline.

The link between telomeres and aging has drawn intense scientific interest. It was even the focus of the 2009 Nobel Prize in Physiology or Medicine. Preventing or reversing telomere shortening can extend a cell’s lifespan in the lab. It may also lead to new therapies for age‑related diseases.

Blau explained the significance of their findings in a press release. “We have found a way to lengthen human telomeres, turning back the internal clock in these cells by the equivalent of many years of human life. This greatly increases the number of cells available for studies such as drug testing or disease modeling.”

Her team’s method uses a modified piece of RNA that boosts production of telomerase, the protein that lengthens telomeres. Telomerase is abundant in stem cells but declines as cells mature. The modified RNA delivers a temporary burst of telomerase, causing aging cells to behave like much younger cells. This youthful effect lasts about 48 hours before the cells return to their usual state.

The temporary boost has clear advantages. It prevents cells from dividing uncontrollably, which reduces the risk of tumor formation. John Ramunas, the study’s first author, also highlighted additional benefits of this short‑term, controlled approach.

“Existing methods of extending telomeres act slowly,” Ramunas said. “Our method works within a few days and reverses telomere shortening that normally occurs over more than a decade of aging. This suggests that a treatment using our method could be brief and infrequent.”

Duchenne muscular dystrophy involves abnormally short telomeres, so Blau believes this discovery could improve treatment options. Her team’s next steps include testing the approach in many different cell types.

As Blau explained, they want to understand how each type responds and how to overcome those differences to make the method more widely effective.

You can learn more about stem cells and muscular dystrophy in our recent Spotlight on Disease featuring Helen Blau.